Psilocybin-based therapy shows rapid relief in treatment-resistant depression, eyeing FDA approval
TL;DR Summary
Compass Pathways reported two positive late-stage trials of a synthetic psilocybin treatment that rapidly reduces symptoms in patients with treatment-resistant depression, potentially becoming the first psychedelic medicine to gain full regulatory approval if the FDA approves it early next year.
- A psychedelic medicine performs well against depression The Economist
- FDA could approve magic mushroom chemical for depression Yahoo Finance
- Compass says its psilocybin drug helped patients with severe depression in two trials statnews.com
- Psychedelics stocks rise as Compass’ psilocybin drug heads to FDA BioPharma Dive
- Investors cheer Compass’ psilocybin data statnews.com
Reading Insights
Total Reads
1
Unique Readers
2
Time Saved
6 min
vs 7 min read
Condensed
97%
1,274 → 40 words
Want the full story? Read the original article
Read on The Economist